Frontlight ResearchEarly access
CompletedNo phase
Short-term Oral Prednisone for Acute Subjective Tinnitus
Key facts
- Who runs it
- Eye & ENT Hospital of Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 146 people enrolled
- Started
- 30 Oct 2022
- Ended
- 3 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Prednisone tablet
- Ginkgo Biloba Extract
- Record updated
- 28 February 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 18-65 years old
- a primary complaint of frequent occurrences of subjective tinnitus lasting at least 5 minutes within the past 3 months
- a definition of normal hearing in line with the World Report on Hearing (2021), of which the average value of hearing threshold at 500, 1000, 2000, 4000 Hz in better ear was less than 20 decibels
- a score of more than 16 points on the Tinnitus Handicap Inventory (THI), which indicates that the level of tinnitus exceeds mild severity
- a state of good general condition
Who cannot take part
- had previous history of middle ear pathology, apparent history of noise exposure, noise trauma or head injury
- had received treatment for their current condition before the study
- taken oral steroids within 3 months before randomization
- had hearing implants
- had a history of known corticosteroid contraindications (including osteoporosis, peptic ulcers, poorly controlled hypertension, diabetes, chronic liver or renal insufficiency, tumorous condition, alcohol abuse, pregnancy, or taking estrogen-containing oral contraceptive steroids)
- auditory hallucinations or other conditions deemed inappropriate for inclusion by the investigator
- had participated in other clinical trials and have not terminated the trials
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to investigate the efficacy of oral steroids in the acute tinnitus population. Participants will receive appropriate dosages of short-term prednisone and/or oral Ginkgo Biloba tablets.
The 2 groups in the trial
- STOP groupTreatment being tested
a 10mg/d tapering 14-day course of oral prednisone intervention (the initial dose: 1mg/kg/day, max 60mg/day) in combination with ginkgo biloba agent (120mg, three times/day)
Treatment: Prednisone tablet and Ginkgo Biloba Extract
- placebol groupPlacebo, for comparison
Patients took oral standardized Ginkgo biloba extracts (120 mg daily) three times a day.
Treatment: Ginkgo Biloba Extract
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigating the Efficacy of Short-term Oral Prednisone Therapy on Acute Subjective Tinnitus
- Record updated
- 28 February 2025